Abstract
Matrix metalloproteinases (MMPs) are a family of zinc-containing enzymes involved in the degradation and remodeling of extracellular matrix proteins. The activities of these enzymes are well regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs). Chronic stimulation of MMP activities due to an imbalance in the levels of MMPs and TIMPs has been implicated in the pathogenesis of a variety of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. Thus, MMP inhibitors are expected to be useful for the treatment of these disorders. This article reviews briefly the biochemistry of MMPs and evidence for their pathogenic roles using molecular biology approaches. Biomolecular structures used in the design of MMP inhibitors are thoroughly covered. Major emphasis is on recently published potent, small molecular weight MMP inhibitors and their pharmacological properties. Finally, available clinical results of compounds in development are summarized.
Keywords: Metalloproteinase inhibitors, angiogenesis, tumor induced, hydroxamate moiety, non peptidic sulfonamide, uninhibited catalytic domain, gelatinase, murine model, spiro cyclopentyl, Biaryl oxime
Current Medicinal Chemistry
Title: The Design, Structure, and Therapeutic Application of Matrix Metalloproteinase Inhibitors
Volume: 8 Issue: 4
Author(s): Jerry W. Skiles, Nina C. Gonnella and Arco Y. Jeng
Affiliation:
Keywords: Metalloproteinase inhibitors, angiogenesis, tumor induced, hydroxamate moiety, non peptidic sulfonamide, uninhibited catalytic domain, gelatinase, murine model, spiro cyclopentyl, Biaryl oxime
Abstract: Matrix metalloproteinases (MMPs) are a family of zinc-containing enzymes involved in the degradation and remodeling of extracellular matrix proteins. The activities of these enzymes are well regulated by endogenous tissue inhibitors of metalloproteinases (TIMPs). Chronic stimulation of MMP activities due to an imbalance in the levels of MMPs and TIMPs has been implicated in the pathogenesis of a variety of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. Thus, MMP inhibitors are expected to be useful for the treatment of these disorders. This article reviews briefly the biochemistry of MMPs and evidence for their pathogenic roles using molecular biology approaches. Biomolecular structures used in the design of MMP inhibitors are thoroughly covered. Major emphasis is on recently published potent, small molecular weight MMP inhibitors and their pharmacological properties. Finally, available clinical results of compounds in development are summarized.
Export Options
About this article
Cite this article as:
Skiles W. Jerry, Gonnella C. Nina and Jeng Y. Arco, The Design, Structure, and Therapeutic Application of Matrix Metalloproteinase Inhibitors, Current Medicinal Chemistry 2001; 8 (4) . https://dx.doi.org/10.2174/0929867013373417
DOI https://dx.doi.org/10.2174/0929867013373417 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Probiotics, Immune Function, Infection and Inflammation: A Review of the Evidence from Studies Conducted in Humans
Current Pharmaceutical Design Design, Synthesis, and Docking Studies of 4H-Chromene and Chromene Based Azo Chromophores: A Novel Series of Potent Antimicrobial and Anticancer Agents
Current Organic Synthesis Recognizing Severe Adverse Drug Reactions: Two Case Reports After Switching Therapies to the Same Generic Company
Current Drug Safety Cancer-related Fatigue, Inflammation and Thyrotropin-releasing Hormone
Current Aging Science Coumarin and Isocoumarin as Serine Protease Inhibitors
Current Pharmaceutical Design Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Interstitial Lung Disease Associated with Polymyositis-Dermatomyositis
Current Respiratory Medicine Reviews The Role of Chemokines in the Pathogenesis of Rheumatoid Arthritis
Current Rheumatology Reviews Autoantibodies Profile in Matching CSF and Serum from AD and aMCI patients: Potential Pathogenic Role and Link to Oxidative Damage
Current Alzheimer Research Modulation of Apoptosis: New Opportunities for Drug Discovery to Treat Autoimmune Thyroiditis
Recent Patents on Inflammation & Allergy Drug Discovery Microarray Technologies for Intracellular Kinome Analysis
Current Medicinal Chemistry Rare Clinical Case of Cryopyrin-associated Periodic Syndrome Presented with Ankylosing Spondylitis: A Case Report
Current Rheumatology Reviews Cytokine Status of Serum in Ovarian Cancer Patients with Different Tumor Neoadjuvant Chemotherapy Response
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Hepatobiliary Transporters by A Novel Kinase Inhibitor Contributes to Hepatotoxicity in Beagle Dogs
Drug Metabolism Letters Chronic Non-bacterial Osteomyelitis in Childhood – a Comprehensive Review
Current Rheumatology Reviews Serum Hepcidin: Its Correlation with Serum Ferritin, Serum Iron and Hemoglobin in Patients of Iron Deficiency Anemia
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design A New Bone Marrow Transplantation Method for the Prevention of Graft- Versus-Host Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents